{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihbs542rzsbr7xndkbxguborzggjojuunzcsi2keuq4loa4p2cqci",
    "uri": "at://did:plc:k7h5fn3kdhjpj37pc6yhno2o/app.bsky.feed.post/3mmgcdjdmjpm2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidjozeu3tyuncfuf3egbe3rb552oswxcj7qfmeymszzmh3z4dbfyy"
    },
    "mimeType": "image/jpeg",
    "size": 70595
  },
  "path": "/article/next-gen-weight-loss-drug-retatrutide-trial-brings-it-one-step-closer-to-fda-approval/",
  "publishedAt": "2026-05-21T15:30:00.000Z",
  "site": "https://www.scientificamerican.com",
  "textContent": "While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors",
  "title": "Trial of next-gen weight-loss drug retatrutide brings it one step closer to FDA approval"
}